In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Efficacy The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea Will be Initiated in 2025 THOUSAND OAKS, Calif. , June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently.
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
![]() AMG 10 months ago | Other | €2.25 Per Share |
![]() AMG 16 May 2024 | Other | €2.25 Per Share |
![]() AMG 15 Feb 2024 | Other | €2.25 Per Share |
![]() AMG 16 Nov 2023 | Other | €2.13 Per Share |
![]() AMG 17 Aug 2023 | Other | €2.13 Per Share |
4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | 4.75 EPS |
29 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() AMG 10 months ago | Other | €2.25 Per Share |
![]() AMG 16 May 2024 | Other | €2.25 Per Share |
![]() AMG 15 Feb 2024 | Other | €2.25 Per Share |
![]() AMG 16 Nov 2023 | Other | €2.13 Per Share |
![]() AMG 17 Aug 2023 | Other | €2.13 Per Share |
4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | 4.75 EPS |
29 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Bradway CEO | XETRA Exchange | US0311621009 ISIN |
US Country | 28,000 Employees | 16 May 2025 Last Dividend | 22 Nov 1999 Last Split | 17 Jun 1983 IPO Date |
Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.